Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial

Дата публикации: 23-06-2026 19:28:25

Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Health Canada Approves Zepbound for OSA in Adults With Obesity	5	8	25-06-2026
2	Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis	2	6	26-06-2026
3	New Pivotal Study Data Released for Takeda’s Oveporexton	5	7	16-06-2026
4	Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X	5	7	16-07-2026
5	The Push Precision OSA Care Needed	0	5	08-07-2026
6	يحسن النوم ويخفف آلام الركبة.. دواء جديد لعلاج السمنة	0	7	06-06-2026
7	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments	2	6	24-06-2026
8	Most obesity drugs do not improve quality of life or heart health, analysis indicates	-2	7	08-07-2026
9	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
10	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	2	7	31-07-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 6. Информативность: 7. Источник: sleepreviewmag.com.